Nasdaq · In Vitro & In Vivo Diagnostic Substances
43 entities across 29 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-02-20 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Saco Street, LLC | Maine | |
| Beijing IDEXX Laboratories Co. Limited | China | |
| IDEXX Animana B.V. | Netherlands | |
| IDEXX Brasil Laboratórios Ltda. | Brazil | |
| IDEXX Brasil Participações Ltda. | Brazil | |
| IDEXX Canada Holdings Corp. | Delaware | |
| IDEXX Diagnostic Limited | Ireland | |
| IDEXX Distribution, Inc. | Massachusetts | |
| IDEXX GmbH | Germany | |
| IDEXX B.V. | Netherlands | |
| IDEXX Holding GmbH | Germany | |
| IDEXX Holdings, Inc. | Delaware | |
| IDEXX Laboratories II (NZ) ULC | New Zealand | |
| IDEXX Laboratories (Proprietary) Limited | South Africa | |
| IDEXX Laboratories (Shanghai) Company Limited | China | |
| IDEXX Laboratories B.V. | Netherlands | |
| IDEXX Laboratories Co., Ltd. | Thailand | |
| IDEXX Laboratories Danmark ApS | Denmark | |
| IDEXX Laboratories Hong Kong Limited | Hong Kong | |
| IDEXX Laboratories Italia S.r.l. | Italy | |
| IDEXX Laboratories, KK | Japan | |
| IDEXX Laboratories Norge AS | Norway | |
| IDEXX Laboratories Oy | Finland | |
| IDEXX Laboratories Philippines, Inc. | Philippines | |
| IDEXX Laboratories Private Limited | India | |
| IDEXX Laboratories Singapore Pte. Ltd. | Singapore | |
| IDEXX Laboratories Sp. z o.o. | Poland | |
| IDEXX Laboratories SRL | Belgium | |
| IDEXX Laboratories Sverige AB | Sweden | |
| IDEXX Laboratories, S.de R.L. de C.V. | Mexico | |
| IDEXX Laboratories s.r.o. | Czech Republic | |
| IDEXXLAB, Unipessoal Lda. | Portugal | |
| IDEXX Laboratorios, S.L. | Spain | |
| IDEXX Montpellier SAS | France | |
| IDEXX Operations, Inc. | Delaware | |
| IDEXX Pharmaceuticals, LLC | Delaware | |
| IDEXX Real Estate Holdings GmbH | Germany | |
| IDEXX Real Estate Holdings, LLC | Maine | |
| IDEXX SARL | France | |
| IDEXX Vet Med Labor GmbH | Austria | |
| Laboratoire IDEXX SARL | France | |
| OPTI Medical Systems, Inc. | Delaware | |
| Vet Med Labor GmbH | Germany |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $2.7B | $581.8M | $541.1M | 58.0% | 86,722,000 |
| FY2021 | $3.2B | $744.8M | $636.0M | 58.8% | 86,572,000 |
| FY2022 | $3.4B | $679.1M | $394.1M | 59.5% | 84,600,000 |
| FY2023 | $3.7B | $845.0M | $772.9M | 59.8% | 83,978,000 |
| FY2024 | $3.9B | $887.9M | $808.1M | 61.0% | 83,246,000 |
| FY2025 | $4.3B | $1.1B | $1.1B | 61.8% | 81,025,000 |
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
IDEXX LABORATORIES INC /DE files under SIC 2835 — all 4 in vitro & in vivo diagnostic substances companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
